Geoffrey Porges Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Geoffrey Porges, which is filed under People. There are 408 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
9/29/2021 AbbVie pressures Biohaven in migraine prevention with FDA approval for its CGRP blockbuster-to-be Qulipta
... Biohaven’s Nurtec ODT as the first oral anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations. For Qulipta, SVB Leerink analyst Geoffrey Porges in August projected about $1.2 billion sales in 2030, which he noted was above Wall ...
9/28/2021 Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts
... Squibb. But the real focus is sotatercept, an experimental drug for pulmonary arterial hypertension (PAH), and that med could spell trouble for the deal with regulators, SVB Leerink analysts Daina Graybosch, Ph.D., and Geoffrey Porges said in separate notes Tuesday. Merck entered the PAH space in 2014 through a licensing ...
9/15/2021 U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron's COVID-19 therapy
... months of 2021. "With COVID cases, hospitalizations, and deaths all elevated again in the U.S., demand is likely to remain high through year-end, and most likely through the winter," SVB Leerink analyst Geoffrey Porges told investors. He predicts that the treatment will generate $5.4 billion in total sales in ...
9/8/2021 GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst FiercePharma
9/2/2021 FDA's new JAK safety restrictions spell trouble for AbbVie's Rinvoq, but to what extent? | FiercePharma FiercePharma
8/16/2021 FibroGen's longtime CFO hands baton to J&J veteran as high-profile roxadustat blowup cues a likely overhaul FiercePharma
8/11/2021 Surprise, surprise: AstraZeneca and FibroGen's once-hyped anemia drug roxadustat hits an FDA wall FiercePharma
5/27/2021 Vir Stock Reverses Despite Gaining FDA Nod For GSK-Partnered Covid Drug | Investor's Business Daily
5/11/2021 FibroGen Inc. (FGEN) Q1 2021 Earnings Call Transcript
5/6/2021 Regeneron Pharmaceuticals Inc. (REGN) Q1 2021 Earnings Call Transcript
4/28/2021 GlaxoSmithKline plc. (GSK) Q1 2021 Earnings Call Transcript
4/28/2021 Clamping Down On Drug Prices Stifles Innovation, Influential Analyst Says | Kaiser Health News Kaiser Health News
4/27/2021 Pharma Industry M&a Scrutiny in Sen. Amy Klobuchar's Book Business Insider
4/16/2021 How mRNA vaccines like Moderna's and Pfizer's are propelling us into the ‘new golden age’ of vaccinology | Fortune Fortune
3/30/2021 MorphoSys, Incyte are touting Monjuvi's potential down the line—but COVID-19 is slowing its launch now FiercePharma
3/23/2021 SVB Leerink's Porges warns biotech stocks could fall, downgrades GSK Business Insider
1/23/2021 Next-generation COVID-19 vaccines: pipeline, challenges, promise Business Insider
1/21/2021 GlaxoSmithKline's ‘serial disappointments’ cast doubt on its growth plans: analyst FiercePharma
12/16/2020 Pharmacquired: What a surprise deal does for AstraZeneca and Alexion BioPharma Dive
12/16/2020 Gilead guts its filgotinib plans, dealing a blow to O'Day's diversification dream FiercePharma
11/24/2020 U.K. could roll out vaccines from Astra-Oxford, Pfizer in December (NASDAQ:AZN) | Seeking Alpha Seeking Alpha
11/10/2020 Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100% Yahoo News
10/22/2020 Investors Brace for Barrage of COVID Vaccine Data to Roil Market | Business News
10/21/2020 Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst Benzinga
10/13/2020 Amgen’s big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors